Introduction
Obstructive sleep apnea syndrome is a common clinical problem effecting approximately 2-4% of the adult population (1) . It is characterized by intermittent and recurrent upper airway occlusion during sleep (2) . The resulting airway narrowing and/or closure restrict airflow and can produce repeated oxyhemoglobin desaturations, sleep fragmentation, or both. Continuous positive airway pressure (CPAP) is a standard treatment for patients with OSA (3, 4) . Positive airway pressure (PAP) is a very effective treatment but only if it is used on a regular basis (5) . A comprehensive review of CPAP literature found non-acceptance rates to vary from 5 to 50%, with the average of approximately 20%. Another 12 to 15% can be expected to stop PAP treatment within 3 years. Of those using PAP, adherence rates (>4 h use for 70% of days) have varied from 40 to 80% (6, 7) . A major challenge facing clinicians is improving adherence to PAP treatment (8) . While the literature mainly supports CPAP therapy, Bi-level PAP (BPAP) is an optional therapy in some cases where high pressure is needed and the patient experiences difficulty exhaling against a fixed pressure (4,9,10). BPAP delivers a separately adjustable lower expiratory positive airway pressure (EPAP) and higher inspiratory positive airway pressure (IPAP) (9, 11) . BiPAP with Bi-Flex offers a unique form of bi-level therapy by which Bi-Flex provides flow-directed modification to the transition into and out of the IPAP phase, and dynamic expiratory pressure relief. The amount of expiratory pressure relief is determined by the patient's expiratory flow. Accordingly, the pressure returns to therapeutic levels prior to the initiation of the next breath's inspiratory phase. The pressure relief offers a more comfortable expiratory experience for the patient, and may impact favorably on perceptions of therapy as well as potentially long-term acceptance to therapy (5) . The primary aim of this study was to examine the performance of BiPAP Auto ® with BiFlex™ (BPAPauto; respironics corporation) device during attended polysomnography (PSG) for the treatment of OSA. Specifically; (1) to automatically adjust EPAP and IPAP pressure to maintain a therapeutic apnea-hypopnea index (AHI), (2) to automatically adjust EPAP and IPAP pressure to maintain airway potency, (3) to maintain low average treatment pressure, and (4) to maintain acceptable sleep architecture.
Materials and Methods

Participants
Subjects with OSA currently using CPAP or BPAP therapy were recruited from the University of Pittsburgh Medical Center (UPMC), Sleep Medicine Center where they have been diagnosed with OSA and are currently being treated with fixed PAP. Patients who met all criteria for participation and provided informed consent were scheduled to undergo in-lab PSG study with BPAPauto with BiFlex. Participants were also asked to bring their own mask and accessories in order to maximize their comfort. Inclusion criteria of the study were; 1. Fixed CPAP users with a prescription ≥8 cmH 2 O or fixed BPAP users with any Bi-Level prescription, 2. The Sleep disordered breathing events were required to be primarily obstructive in nature (>50%), 3. Age ≥18 years, 4. No weight change in excess of ± 15 pounds since last titration (<1 year), 5. Able to follow instructions, 6. Able to provide inform consent. Exclusion criteria were; 1. CPAP prescription of <8 cmH 2 O , 2. An artificial airway, 3. Current acute upper respiratory infection, encephalitis, sinusitis or middle ear infection, 4. Acute dermatitis or other skin lesions or trauma interfering with the application of a mask, 5. Co-morbid conditions including cardiopulmonary diseases, COPD, heart failure or receiving anticoagulants. The study was approved by Western Institutional Review Board (WIRB) and UPMC Clinical Trials Office (CTO). All participants provided informed consent prior to participation in the study.
Design
This was a prospective case series. The study was approved by Western Institutional Review Board (WIRB) and university of Pittsburgh Medical Center Clinical Trials Office (CTO). Participants were recruited from the Sleep Evaluation Center at UPMC, where they have been evaluated and treated for OSA. After obtaining institutional Review Board (IRB) approved informed consent, 27 subjects who met inclusion/exclusion criteria evaluated with BPAP Auto Flex device during attended PSG.
Auto Bi-Level with Bi-Flex
Auto Bi-Level PAP delivers spontaneous Bi-level therapy with automatically adjusting EPAP and IPAP levels. The device is capable of responding to apnea, hypopnea, vibratory snoring, and large air leak events. The Auto Bi-level therapy also incorporates a "pro-active" search algorithm that responds to early indications of airway obstructions. During therapy, the auto Bi-Level PAP device continues to monitor breathing and searches for vibratory snoring, apneas, hypopneas, of flow limitations. The pressure is adjusted in response to an event. Usually, a change occurs over a 15 second period. This approach is based upon a titration protocol that increases EPAP related to obstructive apnea events and increases Pressure Support (PS) based upon obstructive hypopnea, snoring and flow limitation events. The level of pressure support (PS) delivered is determined by the difference between the IPAP and EPAP settings (PS=IPAP-EPAP). In a sleep lab, EPAP is usually adjusted first as the patient goes through various sleep stages and body positions to ensure that obstructive apneas are eliminated under worst-case conditions. PS is then adjusted to eliminate partial airway closure such as hypopneas and snoring. The auto Bi-Level device included a pressure relief feature called Bi-Flex. The Bi-Flex mode provides pressure relief during the latter stages of inspiration and during active exhalation (the beginning part of exhalation). In the Figure 1 , comfort feature of Bi-Flex was presented graphically. Bi-Flex levels of 1, 2, or 3 progressively reflect increased pressure relief that take place at the end of inspiration and at the beginning of expiration. The device was set to deliver between 4 and 25 cmH 2 O for both the inspiratory (IPAP) and expiratory (EPAP) positive airway pressures. IPAP and EPAP were adjusted independently as determined by the device's algorithm. The minimum allowable difference between IPAP and EPAP was 2 cmH 2 O and a maximum difference was 8 cmH 2 O. The device's algorithm determined therapy pressure requirements for the duration of the PSG. Participants received therapy with the auto Bi-Level with Bi-Flex comfort feature.
Polysomnography
Full PSG performed using the SomnoStar Pro™ system (Viasys ® Healthcare). Channels monitored and recorded with surface electrodes included electroencephalogram, electrooculogram and submental electromyogram. Arterial oxygen saturation was recorded by digital pulse oximetry. Chest and abdominal effort were recorded using inductance plethysmography. Airflow was recorded with a pressure transducer attached to the Bi-Level device's pressure outlet. Apnea was defined as complete cessation of airflow for at least 10 seconds; hypopnea was defined as a 50% decrease in airflow and a 4% drop in oxygen saturation. American Academy of Sleep Medicine (AASM) sleep scoring criteria was used for scoring the diagnostic PSG (12).
Statistical Analysis
Standard sleep parameters were collected and analyzed. Baseline demographic data was summarized. For continuous variables such as weight, the mean, standard deviation and range was presented. For categorical variables such as gender, the proportion of participants in each category was presented.
Results
The entire study population comprised 82% (22/27) male and 18% (5/27) female participants. The mean age was 54±16 years and BMI (body mass index) was 33.0±9.1 kg/m 2 . Participant's demographic and baseline PSG data were shown in Table  1 . The mean AHI (apnea hypopnea index) of entire study population obtained from the baseline diagnostic sleep study was 47.0±31.5 events/hour. Thirteen of the 27 participants currently had been using CPAP with a mean pressure of 12 
Discussion
Data obtained from this study showed that BPAPauto is able to determine appropriate Bi-Level positive airway pressure and control oxygen saturation without excessive disruption of sleep. In 1981, nasal continuous positive airway pressure, which acts as a pneumatic splint, was introduced as a treatment of OSA and has been considered the gold standard for treatment of OSA since (13) . Several clinical trials have shown that CPAP eliminates apneic and hypopneic events, improve day time function, quality of life, sustained attention and mood and decrease cardiovascular risk factors (14) (15) (16) (17) . Although highly effective, only half of the patients use CPAP as prescribed (18) . Pressure intolerance could be one of the reasons for decreased (11, 19) . Improving patient tolerance of PAP is one of the main driving forces for the development of alternative modes of PAP. A change in PAP mode may dramatically improve adherence in individual patients (5) . However studies showed that BPAP or APAP treatments do not result in higher adherence (9, 20) . In one study use of C-flex device provided a statistically significant improvement in adherence (21 
